July 16, 1982

CDC MMWR reports immune-suppressive disorder identified in three hemophiliac patients.

July 16, 1982

FDA's Bureau of Biologic meeting to discuss opportunistic infections in hemophiliacs.

July 16, 1982

Public Health Service Working Group on Opportunistic Infections in Hemophiliacs meeting to exchange information about the three cases of AIDS in hemophilia patients.

July 27, 1982

Working Group on Opportunistic Infections in Hemophiliacs second meeting to determine if other groups with acquired immunodeficiency showed similar etiology and if blood products were risk factors for AIDS.

December 10, 1982

CDC MMWR reports four additional cases in hemophiliacs, one suspect case in an infant who had received a blood transfusion.

January 4, 1983

CDC public meeting to identify opportunities to prevent AIDS.

March 4, 1983

Assistant Secretary for Health promulgates the first official PHS recommendations on the prevention of AIDS, including recommendations to avoid sexual contact with persons known or suspected of having AIDS and the increased probability of developing AIDS by having multiple sex partners.

March 24, 1983

FDA notification of all establishments collecting source plasma and human blood for transfusion and manufacturers of plasma derivatives of steps to be taken to decrease the risk of blood or plasma donation by persons who might be at increased risk of transmitting AIDS.

May 11, 1983

Baxter Healthcare recall of a lot of AHF concentrate when it discovers that the product was manufactured from pools containing plasma from an individual subsequently diagnosed as having AIDS.

July 19, 1983

FDA Blood Products Advisory Committee (BPAC) meeting to discuss the criteria for deciding to withdraw lots of AHF concentrate.